Insmed Inc (INSM)vsOmeros Corporation (OMER)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
OMER
Omeros Corporation
$10.44
+2.55%
HEALTHCARE · Cap: $755.80M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates -2121% more annual revenue ($606.42M vs $-30.00M). OMER leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
OMER
Avoid27
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : OMER
Revenue growth of 14.9% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : OMER
The primary concerns for OMER are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while OMER is a value play — different risk/reward profiles.
OMER carries more volatility with a beta of 2.52 — expect wider price swings.
OMER is growing revenue faster at 14.9% — sustainability is the question.
OMER generates stronger free cash flow (-18M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Omeros Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?